普通外文研报
Reminder: Analyst Access: Webinar: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development
研报英文原文证据摘录
Reminder: Analyst Access: Webinar: AI in Healthcare: Adoption, Execution, and Outcomes in Drug Development
James Gordon is a Director and Head of the European
Pharma & Biotech Equity Research team at Barclays.
James joined Barclays in November 2025, having spent
c.20 years covering European Pharma & Biotech at J.P.
Morgan, where he was part of a team consistently top
ranked in the Institutional Investor / Extel survey. Prior to
Healthcare Equity Research James worked in Strategy
Consulting, focusing on Pharmaceuticals. James holds a
1st-class BSc in Genetics from University College London,
with a focus on Population Genetics and Statistics.
View Analyst Page
Emily Field, CFA is a Director and Head of U.S.
Biopharmaceuticals equity research at Barclays. Joining
the bank’s London office in 2017, she previously served as
Head of the European Pharmaceuticals team, earning a #4
individual ranking in European Pharmaceuticals &
Biotechnology in the 2025 Extel survey. With more than
two decades experience across both buy-side and sell-side
roles, she has worked across multiple investing strategies
including risk arbitrage and equity long/short. Prior to
Barclays, Ms. Field held positions at UBS O’Connor and
Millennium Management. Originally hailing from Chicago,
Ms. Field holds a B.A. in Economics and History from Yale
University, graduating with distinction in both majors, and
is a CFA charterholder.
Etzer Darout, PhD, MBA, is a Managing Director and equity
research analyst covering the U.S. Small and Mid-Cap
Biotechnology sector, with over 10 years of sell-side
research experience. Before joining Barclays in June 2025,
Etzer spent three years at BMO Capital Markets as a
Managing Director and senior equity research analyst
covering the Biotechnology sector.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器